RECRUITING

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Description

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participants meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical study.

Conditions

Head and Neck CancerCervical CancerNon Small Cell Lung CancerHPV16 Related CancersSarcomaUveal MelanomaNUT Carcinoma
Talk to us

Related Conditions:

Head and Neck CancerCervical CancerNon Small Cell Lung CancerHPV16 Related CancersSarcomaUveal MelanomaNUT Carcinoma

Study Overview

On this page

Study Details

Study overview

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participants meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical study.

Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumors

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Condition
Head and Neck Cancer
Intervention / Treatment

-

Contacts and Locations

Scottsdale

HonorHealth Research and Innovation Institute, Scottsdale, Arizona, United States, 85258

San Diego

University of California San Diego, San Diego, California, United States, 92037

New Haven

Yale Cancer Center, New Haven, Connecticut, United States, 06510

Hollywood

Memorial Healthcare System, Hollywood, Florida, United States, 33021

Miami

University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States, 33136

Orlando

Orlando Health, Orlando, Florida, United States, 32806

Tampa

University of South Florida, Tampa, Florida, United States, 33606

Chicago

University of Chicago, Chicago, Illinois, United States, 60637

Louisville

Norton Cancer Institute, Louisville, Kentucky, United States, 40202

Detroit

Karmanos Cancer Institute, Detroit, Michigan, United States, 48201

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Willing and able to provide written informed consent.
  • * Male or female aged ≥18 years at the time of signing the informed consent.
  • * Have one of the following histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor for which the Sponsor has an associated clinical study:
  • * Head and neck cancer
  • * Cervical cancer
  • * Non-small cell lung cancer
  • * HPV positive anogenital cancers
  • * Sarcoma
  • * Other cancers with a reasonable likelihood of expressing 1 or more antigens included in a TScan clinical trial, following approval by the TScan Medical Monitor or their delegate.
  • * Willing to provide a buccal swab for HLA testing
  • * Willing to provide a saliva sample to use as a normal control for the LOH assay
  • * Have access to an adequate FFPE tumor block that is \<8 months old or is willing to provide a fresh core-needle biopsy from a location deemed safe by the treating medical team.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

TScan Therapeutics, Inc.,

Dawn Pinchasik, MD, STUDY_DIRECTOR, TScan Therapeutics, Inc.

Study Record Dates

2027-01-14